These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17031483)

  • 21. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
    Nell-Duxneuner V; Schroeder Y; Reichardt B; Bucsics A
    Int J Clin Pharmacol Ther; 2012 Dec; 50(12):867-72. PubMed ID: 23036238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biological treatment of ankylosing spondylitis].
    Freiesleben S; Schou M
    Ugeskr Laeger; 2008 Jun; 170(24):2140-5. PubMed ID: 18565298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anti-TNF alpha in the treatment of rheumatoid arthritis and ankylosing spondylitis].
    Lanfant-Weybel K; Lequerré T; Vittecoq O
    Presse Med; 2009 May; 38(5):774-87. PubMed ID: 19327945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD; Sack KE; Davis JC
    N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
    Braun J; Baraliakos X; Listing J; Sieper J
    Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term management of erythrodermic psoriasis with anti-TNF agents.
    Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
    Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
    Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Onset of Crohn's disease induced by etanercept therapy: a case report].
    Mrabet D; Selmi A; Filali A; Sahli H; Sellami S
    Rev Med Liege; 2012 Dec; 67(12):619-22. PubMed ID: 23342871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
    Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2004 Jun; 63(3):203-10. PubMed ID: 15224223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of ankylosing spondylitis with anti-TNFalpha agents].
    Bontoux D; Azaïs I; Goupille P
    Bull Acad Natl Med; 2006; 190(4-5):981-92; discussion 993-4. PubMed ID: 17195622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists.
    Gottlieb GS; Lesser CF; Holmes KK; Wald A
    Clin Infect Dis; 2003 Sep; 37(6):838-40. PubMed ID: 12955647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diverse effects of infliximab and etanercept on T lymphocytes.
    Sieper J; Van Den Brande J
    Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):23-7. PubMed ID: 15852251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance.
    Wailoo A; Bansback N; Chilcott J
    Rheumatology (Oxford); 2008 Feb; 47(2):119-20. PubMed ID: 18208819
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapeutic use of anti-TNF-alpha agents in spondyloarthropathies].
    Wendling D; Claudepierre P; Lohse A; Toussirot E; Breban M
    Presse Med; 2003 Oct; 32(32):1517-24. PubMed ID: 14534471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aortitis during etanercept therapy for ankylosing spondylitis: finding the culprit.
    Verhoeven F; Bossert M; Lohse-Walliser A; Balblanc JC
    Joint Bone Spine; 2012 Oct; 79(5):524-6. PubMed ID: 22575065
    [No Abstract]   [Full Text] [Related]  

  • 40. Alopecia areata during etanercept therapy.
    Pan Y; Rao NA
    Ocul Immunol Inflamm; 2009; 17(2):127-9. PubMed ID: 19412875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.